Synaffix Alternatives & Competitors
10 companies similar to Synaffix — A Lonza Company
Companies similar to Synaffix
Oxford BioTherapeutics
Redefining the cancer-immune synapse for novel immune checkpoint mechanisms
Oxford, United Kingdom
NextPoint Therapeutics, Inc.
Launching a new world of precision therapeutics through its leading scientific work on th...
Araris Biotech AG
Building tomorrow's antibody-drug conjugates (ADCs)
Switzerland
Iksuda Therapeutics
Creating class-leading ADCs with enhanced tumor specificity
Newcastle Upon Tyne, Unit...
Track all Synaffix competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Bright Peak Therapeutics
Better Biologics Through Chemistry
Basel, Switzerland
Merus N.V.
Oncology company developing Biclonics® bispecific antibody therapeutics. See our Community...
Utrecht, The Netherlands
Antharis Therapeutics, Inc.
Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting...
San Diego, United States
NBE-Therapeutics AG
Next generation antibody drug conjugates
Basel, Switzerland
Orum Therapeutics
A public biotechnology company pioneering a novel class of protein degraders.
Lexington, United States
About Synaffix
Synaffix, a Lonza Company, is a pioneering biotech firm founded in 2014 and headquartered in The Netherlands. It boasts a proprietary, clinical-stage technology platform focused on antibody-drug conjugates (ADCs), renowned for optimizing safety and efficacy. The platform's value is underscored by more than $7.6 billion...
ADC Platform Licensing, Bispecific Antibody Development, Targeted Therapy Development, Out-licensing Technology for Cancer Therapeutics
Pharmaceutical Companies, Biotechnology Firms, Oncology Researchers, Strategic Partners in Therapeutics
Antibody-Drug Conjugates, ADC Technology Platform, Licensed Partnerships, Biotech Innovation, Clinical-Stage Development, Enzymatic Glycan Modification, Metal-Free Click Chemistry, Site-Specific Conjugation, Cancer Therapeutics, Immune Cell Engagers, Targeted Gene Therapy, Bispecific Antibodies, Patent Portfolio, Phase 1 Clinical Trials, High Growth Market Segments
B2B, Platform, API
Licensing, Service Fee, Performance Based
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Synaffix and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Synaffix on 11 Mar 2026. The 10 companies listed here were last checked between 25 Mar 2025 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
